View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 2, 2018

M&As this week: JW Pharmaceutical, Lonza, Karo Intressenter

JW Pharmaceutical has acquired a 25% stake in Argonaut Therapeutics through a $2.6m investment.

JW Pharmaceutical has acquired a 25% stake in Argonaut Therapeutics through a $2.6m investment.

This move makes JW Pharmaceutical the second biggest shareholder of Argonaut after Oxford Sciences Innovation.

Argonaut is developing protein arginine N-methyltransferase 5 (PRMT5) inhibitors as a targeted anticancer agent, which is said to have high selectivity compared with currently available drugs in the market.

The investment will be utilised to develop the PRMT5 inhibitors as a potential treatment for brain, pancreatic and metastatic gastric cancer.

JW Pharmaceutical is based in South Korea, while Argonaut is a UK-based start-up company of the University of Oxford that focuses on the development of next-generation oncology medicine.

Lonza has acquired a majority stake in Octane Biotech.

This stake will allow the chemicals and biotechnology company to further develop the Cocoon™ system, a patient-scale, automated cell therapy manufacturing solution that is the result of a three-year collaboration between the two companies.

“MC Healthcare plans to support business development for services platform Caresyntax by acquiring a minority stake in the firm.”

The acquisition will help Lonza meet growing needs for scalable autologous manufacturing.

The company also along gains the rights to acquire complete ownership of Octane Biotech in the future.

Based in Switzerland, Lonza is a biotechnology company, while Octane Biotech is based in Canada.

Karo Intressenter has made a public cash offer to Karo Pharma Aktiebolag’s shareholders for the acquisition of company shares.

Based in Sweden, Karo Intressenter is a subsidiary of EQT VIII, which is a closed private equity fund owned by EQT. Karo Pharma is a healthcare company that is also based in Sweden.

MC Healthcare plans to support business development for services platform Caresyntax by acquiring a minority stake in the firm.

The Canadian hospital solutions manufacturing company intends to develop Caresyntax’s internet-of-things (IoT), automation and other analytics solutions for care applications.

The solutions will also provide high-quality medical treatment and assistance in hospital operations.

Caresyntax is a surgical technology and services provider based in the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology